Liquidia Technologies Inc (LQDA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Liquidia Technologies Inc (LQDA) has a cash flow conversion efficiency ratio of 0.488x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($52.99 Million) by net assets ($108.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Liquidia Technologies Inc net asset quality index to measure how much of total assets are equity-financed.
Liquidia Technologies Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Liquidia Technologies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Liquidia Technologies Inc (LQDA) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Liquidia Technologies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Liquidia Technologies Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gigabyte Technology Co Ltd
TW:2376
|
-0.049x |
|
Eva Airways Corp
TW:2618
|
0.179x |
|
Shanghai Putailai New Energy Technology Co.Ltd.
SHG:603659
|
0.046x |
|
STAG Industrial Inc
NYSE:STAG
|
0.041x |
|
Klarna Group plc
NYSE:KLAR
|
0.180x |
|
NEXTDC Ltd
AU:NXT
|
0.009x |
|
Yunnan Chuangxin New Material Co Ltd
SHE:002812
|
0.025x |
|
NH Investment & Securities Co Ltd
KO:005940
|
-0.481x |
Annual Cash Flow Conversion Efficiency for Liquidia Technologies Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Liquidia Technologies Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Liquidia Technologies Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $44.75 Million | $-35.69 Million | -0.797x | +34.03% |
| 2024-12-31 | $77.28 Million | $-93.42 Million | -1.209x | -37.56% |
| 2023-12-31 | $47.29 Million | $-41.56 Million | -0.879x | -177.98% |
| 2022-12-31 | $90.42 Million | $-28.59 Million | -0.316x | +39.37% |
| 2021-12-31 | $65.27 Million | $-34.03 Million | -0.521x | +31.53% |
| 2020-12-31 | $71.09 Million | $-54.14 Million | -0.762x | +44.87% |
| 2019-12-31 | $34.95 Million | $-48.28 Million | -1.382x | +18.89% |
| 2018-12-31 | $18.69 Million | $-31.83 Million | -1.703x | -336.26% |
| 2017-12-31 | $-33.69 Million | $-24.29 Million | 0.721x | -5.68% |
| 2016-12-31 | $-18.25 Million | $-13.95 Million | 0.764x | -- |
About Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung diseas… Read more